{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"39.6","value":"35.2"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"21.0","value":"16.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"446"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"description":"ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 31 Months)","title":"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}